Matthew J. Ellis, MD, PhD

Articles

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

October 2nd 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.

Dr. Ellis Considers the Use of Biosimilars in Oncology

August 22nd 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.

Dr. Ellis on the Entrance of Biosimilars Into the Field of Oncology

August 6th 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the entrance of biosimilars into the field of oncology.

Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer

August 1st 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.

Dr. Ellis on Resistance to Endocrine Therapy in HR+ Metastatic Breast Cancer

July 13th 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.

Dr. Ellis on Immunotherapy in HER2+ Breast Cancer

January 23rd 2018

Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.

Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast Cancer

May 28th 2017

Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast Cancer

March 16th 2017

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

Dr. Matthew Ellis Discusses the FALCON Trial

December 13th 2013

Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.

Dr. Matthew J. Ellis on the Future of TCGA

August 27th 2013

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Dr. Ellis on Heterogeneity Impacting Biomarker Efficacy

May 9th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

Dr. Ellis Describes Breast Cancer Heterogeneity

March 27th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

Dr. Ellis on Genome Forward Breast Cancer Treatment

September 26th 2011

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

Dr. Ellis on Hopeful ER+/HER2- Breast Cancer Paradigms

September 14th 2011

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

Dr. Ellis on Measuring Endocrine Therapy Efficacy

September 6th 2011

Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67

Dr. Ellis on Ki67 as Treatment Monitoring Biomarkers

August 31st 2011

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

Dr. Ellis Discusses the Future of the PI3-Kinase Pathway

August 26th 2011

Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway

Dr. Ellis Discusses the Cell-Proliferation Marker Ki67

August 24th 2011

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67